GPT and metabolic dysfunction-associated steatohepatitis: Furthermore, subsequent to AB23A treatment, the activities of ALT and AST in serum along with the liver TG level exhibited varying degrees of improvement relative to the NASH group, indicative of AB23A's ability to effectively restore liver function and ameliorate hepatic steatosis in NASH mice (Figure 5E–G).